Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kyogo Itoh

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Anatomy

Chemicals & Drugs

Physiology

Procedures

Immunotherapy

Concepts & Ideas

Molecular Sequence Data

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
75
Shichijo, Shigeki
73
Yamada, Akira
44
Harada, Mamoru
36
Noguchi, Masanori
27
Yamana, Hideaki
24
Komatsu, Nobukazu
22
Matsueda, Satoko
20
Mine, Takashi
18
Nakao, M
18
Sata, Michio
17
Takedatsu, Hiroko
17
Yutani, Shigeru
17
Maeda, Yoshiaki
16
Komohara, Yoshihiro
16
Azuma, Koichi

Sign-in to see all Coauthors

Publications

TOP 3
Niu Yamei; Terasaki Yasunobu; Komatsu Nobukazu; Noguchi Masanori; Shichijo Shigeki; Itoh Kyogo
Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
Hattori Takashi; Mine Takashi; Komatsu Nobukazu; Yamada Akira; Itoh Kyogo; Shiozaki Hitoshi; Okuno Kiyotaka
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Terasaki Yasunobu; Shichijo Shigeki; Niu Yamei; Komatsu Nobukazu; Noguchi Masanori; Todo Satoru; Itoh Kyogo
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kyogo Itoh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Niu Yamei; Terasaki Yasunobu; Komatsu Nobukazu; Noguchi Masanori; Shichijo Shigeki; Itoh Kyogo
Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
Cancer science 2009;100(11):2167-74.
2009: Hattori Takashi; Mine Takashi; Komatsu Nobukazu; Yamada Akira; Itoh Kyogo; Shiozaki Hitoshi; Okuno Kiyotaka
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Cancer immunology, immunotherapy : CII 2009;58(11):1843-52.
2009: Terasaki Yasunobu; Shichijo Shigeki; Niu Yamei; Komatsu Nobukazu; Noguchi Masanori; Todo Satoru; Itoh Kyogo
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
Cancer immunology, immunotherapy : CII 2009;58(11):1877-85.
2009: Yutani Shigeru; Komatsu Nobukazu; Shichijo Shigeki; Yoshida Kazumi; Takedatsu Hiroko; Itou Minoru; Kuromatu Ryoko; Ide Tatsuya; Tanaka Masatoshi; Sata Michio; Yamada Akira; Itoh Kyogo
Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles.
Cancer science 2009;100(10):1935-42.
2009: Niu Yamei; Komatsu Nobukazu; Komohara Yoshihiro; Matsueda Satoko; Yutani Shigeru; Ishihara Yuki; Itou Minoru; Yamada Akira; Itoh Kyogo; Shichijo Shigeki
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles.
Journal of medical virology 2009;81(7):1232-40.
2009: Azuma Koichi; Sasada Tetsuro; Kawahara Akihiko; Takamori Sinzo; Hattori Satoshi; Ikeda Jiro; Itoh Kyogo; Yamada Akira; Kage Masayoshi; Kuwano Michihiko; Aizawa Hisamichi
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Lung cancer (Amsterdam, Netherlands) 2009;64(3):326-33.
2009: Mohamed Elnisr Rashed; Naito Masayasu; Terasaki Yasunobu; Niu Yamei; Gohara Shojiro; Komatsu Nobukazu; Shichijo Shigeki; Itoh Kyogo; Noguchi Masanori
Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
International journal of oncology 2009;34(2):529-36.
2009: Itoh Kyogo; Yamada Akira; Mine Takashi; Noguchi Masanori
Recent advances in cancer vaccines: an overview.
Japanese journal of clinical oncology 2009;39(2):73-80.
2008: Naito Masayasu; Itoh Kyogo; Komatsu Nobukazu; Yamashita Yuichi; Shirakusa Takafumi; Yamada Akira; Moriya Fukuko; Ayatuka Hitoshi; Mohamed Elnisr Rashed; Matsuoka Kei; Noguchi Masanori
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
The Prostate 2008;68(16):1753-62.
2008: Hatakeyama Seisuke; Matsuoka Yusuke; Ueshiba Hidehiro; Komatsu Nobukazu; Itoh Kyogo; Shichijo Shigeki; Kanai Takao; Fukushi Masaya; Ishida Isao; Kirikae Teruo; Sasazuki Takehiko; Miyoshi-Akiyama Tohru
Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus.
Virology 2008;380(1):99-108.
2008: Gohara Shojiro; Shichijo Shigeki; Komatsu Nobukazu; Okuda Seiya; Yutani Shigeru; Itoh Kyogo
Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infection.
Viral immunology 2008;21(3):365-9.
2008: Noguchi Masanori; Kakuma Tatsuyuki; Tomiyasu Katsuro; Yamada Akira; Itoh Kyogo; Konishi Fumiko; Kumamoto Shoichiro; Shimizu Kuniyoshi; Kondo Ryuichiro; Matsuoka Kei
Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms.
Asian journal of andrology 2008;10(5):777-85.
2008: Jin Mingyue; Komohara Yoshihiro; Shichijo Shigeki; Yamanaka Ryuya; Nikawa Junichi; Itoh Kyogo; Yamada Akira
Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients.
Cancer science 2008;99(8):1656-62.
2008: Komatsu Nobukazu; Harada Mamoru; Nakagawa Masami; Tanaka Yasuaki; Ono Takeharu; Gohara Shojiro; Ohkubo Kimihiko; Itoh Kyogo
A correlation between symptom severity and unbalanced reactive IgA production in Japanese cedar pollinosis patients.
Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand 2008;26(2-3):97-104.
2008: Jin Mingyue; Komohara Yoshihiro; Shichijo Shigeki; Harada Mamoru; Yamanaka Ryuya; Miyamoto Shigeaki; Nikawa Junichi; Itoh Kyogo; Yamada Akira
Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.
Oncology reports 2008;19(5):1277-83.
2007: Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
British journal of cancer 2007;97(12):1648-54.
2007: Komohara Yoshihiro; Harada Mamoru; Ishihara Yuki; Suekane Shigetaka; Noguchi Masanori; Yamada Akira; Matsuoka Kei; Itoh Kyogo
HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Oncology reports 2007;18(6):1463-8.
2007: Suekane Shigetaka; Nishitani Masaaki; Noguchi Masanori; Komohara Yoshihiro; Kokubu Takako; Naitoh Masayasu; Honma Shigenori; Yamada Akira; Itoh Kyogo; Matsuoka Kei; Kanayama Hiroomi
Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients.
Cancer science 2007;98(12):1965-8.
2007: Itoh Yukoh; Komohara Yoshihiro; Komatsu Nobukazu; Minami Takafumi; Saito Koujiro; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
Oncology reports 2007;18(5):1231-7.
2007: Yutani Shigeru; Yamada Akira; Yoshida Kazumi; Takao Yukari; Tamura Mayumi; Komatsu Nobukazu; Ide Tatsuya; Tanaka Masatoshi; Sata Michio; Itoh Kyogo
Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
Vaccine 2007;25(42):7429-35.
2007: Azuma Koichi; Komohara Yoshihiro; Sasada Tetsuro; Terazaki Yasuhiro; Ikeda Jiro; Hoshino Tomoaki; Itoh Kyogo; Yamada Akira; Aizawa Hisamichi
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Cancer science 2007;98(9):1336-43.
2007: Takao Yukari; Yamada Akira; Yutani Shigeru; Ono Takeharu; Nagao Yumiko; Ando Eiji; Ide Tatsuya; Itoh Kyogo; Sata Michio
Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients.
Medical microbiology and immunology 2007;196(3):157-64.
2007: Matsueda Satoko; Yamada Akira; Takao Yukari; Tamura Mayumi; Komatsu Nobukazu; Yutani Shigeru; Ide Tatsuya; Sata Michio; Itoh Kyogo
A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
Cancer immunology, immunotherapy : CII 2007;56(9):1359-66.
2007: Homma Shigenori; Komohara Yoshihiro; Harada Mamoru; Saya Hideyuki; Todo Satoru; Itoh Kyogo; Noguchi Masanori
Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer.
Oncology reports 2007;18(2):343-6.
2007: Tanaka Masahiro; Komatsu Nobukazu; Terakawa Naoyoshi; Yanagimoto Yasuaki; Oka Masao; Sasada Tetsuro; Mine Takashi; Gouhara Shojiro; Shichijo Shigeki; Okuda Seiya; Itoh Kyogo
Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.
Oncology reports 2007;18(1):161-6.
2007: Sato Yuji; Fujiwara Toshiyoshi; Mine Takashi; Shomura Hiroki; Homma Shigenori; Maeda Yoshiaki; Tokunaga Naoyuki; Ikeda Yoshihiro; Ishihara Yuki; Yamada Akira; Tanaka Noriaki; Itoh Kyogo; Harada Mamoru; Todo Satoru
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
Cancer science 2007;98(7):1113-9.
2007: Noguchi Masanori; Yao Akihisa; Harada Mamoru; Nakashima Osamu; Komohara Yoshihiro; Yamada Satoko; Itoh Kyogo; Matsuoka Kei
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
The Prostate 2007;67(9):933-42.
2007: Yamanaka Ryuya; Itoh Kyogo
Peptide-based immunotherapeutic approaches to glioma: a review.
Expert opinion on biological therapy 2007;7(5):645-9.
2007: Minami Takafumi; Matsueda Satoko; Takedatsu Hiroko; Tanaka Masahiro; Noguchi Masanori; Uemura Hirotsugu; Itoh Kyogo; Harada Mamoru
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
Cancer immunology, immunotherapy : CII 2007;56(5):689-98.
2007: Matsueda Satoko; Takedatsu Hiroko; Sasada Tetsuro; Azuma Koichi; Ishihara Yuki; Komohara Yoshihiro; Noguchi Masanori; Shichijo Shigeki; Itoh Kyogo; Harada Mamoru
New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(3):274-81.
2007: Yanagimoto Hiroaki; Mine Takashi; Yamamoto Koutaro; Satoi Sohei; Terakawa Naoyoshi; Takahashi Kanji; Nakahara Kimika; Honma Shigenori; Tanaka Masahiro; Mizoguchi Junko; Yamada Akira; Oka Masaaki; Kamiyama Yasuo; Itoh Kyogo; Takai Soichiro
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
Cancer science 2007;98(4):605-11.
2007: Yamanaka Ryuya; Itoh Kyogo
[Peptide vaccination therapy for malignant glioma]
Brain and nerve = Shinkei kenkyu no shinpo 2007;59(3):251-61.
2007: Takao Yukari; Yamada Akira; Yutani Shigeru; Takedatsu Hiroko; Ono Takeharu; Etoh Kojyu; Wang Yi; Suzuki Susumu; Ide Tatsuya; Shimotohno Kunitada; Sata Michio; Itoh Kyogo
Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients.
Hepatology research : the official journal of the Japan Society of Hepatology 2007;37(3):186-95.
2007: Komohara Yoshihiro; Harada Mamoru; Arima Yoshimi; Suekane Shigetaka; Noguchi Masanori; Yamada Akira; Itoh Kyogo; Matsuoka Kei
Identification of target antigens in specific immunotherapy for renal cell carcinoma.
The Journal of urology 2007;177(3):1157-62.
2007: Harada Mamoru; Ishihara Yuki; Itoh Kyogo; Yamanaka Ryuya
Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
Oncology reports 2007;17(3):629-36.
2007: Komohara Y; Suekane S; Noguchi M; Matsuoka K; Yamada A; Itoh K
Expression of APOBEC3G in kidney cells.
Tissue antigens 2007;69(1):95-8.
2007: Noguchi Masanori; Mine Takashi; Yamada Akira; Obata Yayoi; Yoshida Kazumi; Mizoguchi Junko; Harada Mamoru; Suekane Shigetaka; Itoh Kyogo; Matsuoka Kei
Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
Oncology research 2007;16(7):341-9.
2006: Komohara Yoshihiro; Harada Mamoru; Arima Yoshimi; Suekane Shigetaka; Noguchi Masanori; Yamada Akira; Itoh Kyogo; Matsuoka Kei
Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
International journal of oncology 2006;29(6):1555-60.
2006: Homma Shigenori; Noguchi Masanori; Sato Yuji; Maeda Yoshiaki; Shomura Hiroki; Komohara Yoshihiro; Mine Takashi; Harada Mamoru; Yamada Akira; Todo Satoru; Itoh Kyogo
[Acquired tumor "robustness" in the case of prostate cancer]
Gan to kagaku ryoho. Cancer & chemotherapy 2006;33(12):1748-50.
2006: Hattori Takashi; Okuno Kiyotaka; Yoshida Kazumi; Kokubu Takako; Mine Takashi; Yamada Ryou; Itoh Kyogo; Shiozaki Hitoshi
[A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer]
Gan to kagaku ryoho. Cancer & chemotherapy 2006;33(12):1745-7.
2006: Komohara Yoshihiro; Yano Hirohisa; Shichijo Shigeki; Shimotohno Kunitada; Itoh Kyogo; Yamada Akira
High expression of APOBEC3G in patients infected with hepatitis C virus.
Journal of molecular histology 2006;37(8-9):327-32.
2006: Itoh Kyogo; Yamada Akira
Personalized peptide vaccines: a new therapeutic modality for cancer.
Cancer science 2006;97(10):970-6.
2006: Homma Shigenori; Harada Mamoru; Yano Hirohisa; Ogasawara Sachiko; Shichijo Shigeki; Matsueda Satoko; Komatsu Nobukazu; Shomura Hiroki; Maeda Yoshiaki; Sato Yuji; Todo Satoru; Itoh Kyogo
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
International journal of oncology 2006;29(3):577-87.
2006: Sugita Sunao; Takase Hiroshi; Taguchi Chikako; Imai Yasuhisa; Kamoi Koju; Kawaguchi Tatsushi; Sugamoto Yoshiharu; Futagami Yuri; Itoh Kyogo; Mochizuki Manabu
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Investigative ophthalmology & visual science 2006;47(6):2547-54.
2006: Wang Yi; Takao Yukari; Harada Mamoru; Komatsu Nobukazu; Ono Takeharu; Sata Michio; Itoh Kyogo; Yamada Akira
Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
Cellular immunology 2006;241(1):38-46.
2006: Uemura Hirotsugu; Fujimoto Kiyohide; Tanaka Motoyoshi; Yoshikawa Motoyoshi; Hirao Yoshihiko; Uejima Shigeya; Yoshikawa Kazuhiro; Itoh Kyogo
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1768-75.
2006: Ono Takeharu; Harada Mamoru; Yamada Akira; Tanaka Masahiro; Takao Yukari; Tanaka Yasuaki; Mine Takashi; Sakamoto Kikuo; Nakashima Tadashi; Itoh Kyogo
Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1325-32.
2006: Wang Yi; Harada Mamoru; Yano Hirohisa; Ogasawara Sachiko; Tanaka Masahiro; Yamada Akira; Itoh Kyogo
Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.
Oncology reports 2006;15(2):317-21.
2006: Yamada Akira; Yano Hirohisa; Takao Yukari; Ono Takeharu; Matsumoto Tomoko; Itoh Kyogo
Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic anaphylaxis.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(2):857-63.
2006: Tanaka Masahiro; Komatsu Nobukazu; Yanagimoto Yasuaki; Oka Masao; Shichijo Shigeki; Okuda Seiya; Itoh Kyogo
Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes.
The Kurume medical journal 2006;53(3-4):63-70.
2006: Wang Yi; Takao Yukari; Harada Mamoru; Yutani Shigeru; Ide Tatsuya; Sata Michio; Itoh Kyogo; Yamada Akira
New epitope peptides derived from hepatitis C virus (HCV) 2a which have the capacity to induce cytotoxic T lymphocytes in HLA-A2+ HCV-infected patients.
Microbiology and immunology 2006;50(11):857-65.
2005: Wang Yi; Harada Mamoru; Yano Hirohisa; Ogasawara Sachiko; Takedatsu Hiroko; Arima Yoshimi; Matsueda Satoko; Yamada Akira; Itoh Kyogo
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):535-41.
2005: Hara Miho; Matsueda Satoko; Tamura Mayumi; Takedatsu Hiroko; Tanaka Masahiro; Kawano Kouichiro; Mochizuki Kazuo; Kamura Toshiharu; Itoh Kyogo; Harada Mamoru
Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
International journal of oncology 2005;27(5):1371-9.
2005: Matsueda Satoko; Takedatsu Hiroko; Yao Akihisa; Tanaka Masahiro; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6933-43.
2005: Arima Yoshimi; Matsueda Satoko; Yano Hirohisa; Harada Mamoru; Itoh Kyogo
Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types.
International journal of oncology 2005;27(4):981-8.
2005: Yajima Naoki; Yamanaka Ryuya; Mine Takashi; Tsuchiya Naoto; Homma Jumpei; Sano Masakazu; Kuramoto Terukazu; Obata Yayoi; Komatsu Nobukazu; Arima Yoshimi; Yamada Akira; Shigemori Minoru; Itoh Kyogo; Tanaka Ryuichi
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5900-11.
2005: Tamura Mayumi; Yamada Akira; Takao Yukari; Matsueda Satoko; Komatsu Nobukazu; Yutani Shigeru; Ide Tatsuya; Sata Michio; Itoh Kyogo
Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patients.
Hepatology research : the official journal of the Japan Society of Hepatology 2005;32(4):227-34.
2005: Takedatsu Hiroko; Yoshimoto Kohji; Okamura Takashi; Miyazaki Hiroshi; Kuwaki Tomoaki; Sata Michio; Itoh Kyogo
Determination of thrombopoietin-derived peptides recognized by both cellular and humoral immunities in healthy donors and patients with thrombocytopenia.
Stem cells (Dayton, Ohio) 2005;23(7):975-82.
2005: Harada Mamoru; Matsueda Satoko; Yao Akihisa; Noguchi Masanori; Itoh Kyogo
Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):368-75.
2005: Shichijo Shigeki; Ito Masaaki; Azuma Kouichi; Komatsu Nobukazu; Maeda Yoshiaki; Ishihara Yuki; Nakamura Toru; Harada Mamoru; Itoh Kyogo
A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients.
European journal of cancer (Oxford, England : 1990) 2005;41(9):1323-30.
2005: Takedatsu Hiroko; Yoshimoto Kohji; Okamura Takashi; Yakushij Kazuaki; Imamura Rie; Hashiguchi Michitoshi; Seki Ritsuko; Obata Yayoi; Harada Mamoru; Yamada Akira; Yamana Hideaki; Sata Michio; Itoh Kyogo
Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancy.
International journal of oncology 2005;26(6):1605-12.
2005: Hosokawa Mami; Kadota Ritsuko; Shichijo Shigeki; Itoh Kyogo; Dmitriev Igor; Krasnykh Victor; Curiel David T; Takue Yoichi; Wakasugi Hiro; Takashima Shigemitsu; Heike Yuji
Cell cycle arrest and apoptosis induced by SART-1 gene transduction.
Anticancer research 2005;25(3B):1983-90.
2005: Shichijo Shigeki; Ishihara Yuki; Azuma Kouichi; Komatsu Nobukazu; Higashimoto Noriko; Ito Masaaki; Nakamura Toru; Ueno Takato; Harada Mamoru; Itoh Kyogo
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
Oncology reports 2005;13(5):907-13.
2005: Yamamoto Koutaro; Mine Takashi; Katagiri Kazuko; Suzuki Nobuaki; Kawaoka Toru; Ueno Tomio; Matsueda Satoko; Yamada Akira; Itoh Kyogo; Yamana Hideaki; Oka Masaaki
Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
Oncology reports 2005;13(5):874-83.
2005: Harada Mamoru; Itoh Kyogo
[HLA-restricted cancer-specific killer T cells]
Nippon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 4():579-84.
2005: Noguchi Masanori; Itoh Kyogo; Yao Akihisa; Mine Takashi; Yamada Akira; Obata Yayoi; Furuta Masatoshi; Harada Mamoru; Suekane Shigetaka; Matsuoka Kei
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
The Prostate 2005;63(1):1-12.
2005: Yao Akihisa; Harada Mamoru; Matsueda Satoko; Ishihara Yuki; Shomura Hiroki; Takao Yukari; Noguchi Masanori; Matsuoka Kei; Hara Isao; Kamidono Sadao; Itoh Kyogo
New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
The Prostate 2005;62(3):233-42.
2004: Shichijo S; Keicho N; Long H T; Quy T; Phi N C; Ha L D; Ban V V; Itoyama S; Hu C-J; Komatsu N; Kirikae T; Kirikae F; Shirasawa S; Kaji M; Fukuda T; Sata M; Kuratsuji T; Itoh K; Sasazuki T
Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long-lasting immunity.
Tissue antigens 2004;64(5):600-7.
2004: Azuma Koichi; Sasada Tetsuro; Takedatsu Hiroko; Shomura Hiroki; Koga Makoto; Maeda Yoshiaki; Yao Akihisa; Hirai Tatsuya; Takabayashi Arimichi; Shichijo Shigeki; Itoh Kyogo
Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6695-702.
2004: Shichijo Shigeki; Azuma Kouichi; Komatsu Nobukazu; Ito Masaaki; Maeda Yoshiaki; Ishihara Yuki; Itoh Kyogo
Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5828-36.
2004: Harada Mamoru; Matsueda Satoko; Yao Akihisa; Ogata Rika; Noguchi Masanori; Itoh Kyogo
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Oncology reports 2004;12(3):601-7.
2004: Ogata Rika; Matsueda Satoko; Yao Akihisa; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
The Prostate 2004;60(4):273-81.
2004: Matsueda Satoko; Yao Akihisa; Ishihara Yuki; Ogata Rika; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
The Prostate 2004;60(3):205-13.
2004: Shomura Hiroki; Shichijo Shigeki; Komatsu Nobukazu; Matsueda Satoko; Mine Takashi; Rikimaru Toru; Sato Yuji; Todo Satoru; Itoh Kyogo
Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients.
European journal of cancer (Oxford, England : 1990) 2004;40(11):1776-86.
2004: Takedatsu Hiroko; Okamura Takashi; Yoshimoto Kohji; Harada Mamoru; Koga Makoto; Shichijo Shigeki; Sata Michio; Itoh Kyogo
Expression of epithelial cancer-related antigens in hematologic malignancies applicable for peptide-based immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(4):289-97.
2004: Azuma Koichi; Shichijo Shigeki; Shomura Hiroki; Matsueda Satoko; Fujii Teruhiko; Itoh Kyogo
Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
Breast cancer research and treatment 2004;86(1):19-29.
2004: Mochizuki Kazuo; Sato Yuji; Tsuda Naotake; Shomura Hiroki; Sakamoto Masaru; Matsuura Kimio; Ushijima Kimio; Maeda Yoshiaki; Katagiri Kazuko; Yamada Akira; Todo Satoru; Kamura Toshiharu; Harada Mamoru; Itoh Kyogo
Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen.
International journal of oncology 2004;25(1):121-31.
2004: Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
British journal of cancer 2004;91(2):287-96.
2004: Bednarczuk Tomasz; Hiromatsu Yuji; Seki Naoko; Ploski Rafal; Fukutani Tomoka; Kurylowicz Alina; Jazdzewski Krystian; Chojnowski Krzysztof; Itoh Kyogo; Nauman Janusz
Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy.
Human immunology 2004;65(6):632-9.
2004: Noguchi Masanori; Itoh Kyogo; Suekane Shigetaka; Morinaga Akiko; Sukehiro Aki; Suetsugu Norie; Katagiri Kazuko; Yamada Akira; Noda Shinshi
Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
The Prostate 2004;60(1):32-45.
2004: Matsueda Satoko; Kobayashi Kazuhiko; Nonaka Yoichi; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Cancer immunology, immunotherapy : CII 2004;53(6):479-89.
2004: Hattori Takako Saisho; Komatsu Nobukazu; Shichijo Shigeki; Itoh Kyogo
Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2004;58(4):226-30.
2004: Sasada Tetsuro; Takedatsu Hiroko; Azuma Koichi; Koga Makoto; Maeda Yoshiaki; Shichijo Shigeki; Shoumura Hiroki; Hirai Tatsuya; Takabayashi Arimichi; Itoh Kyogo
Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients.
Cancer research 2004;64(8):2882-8.
2004: Shomura H; Shichijo S; Matsueda S; Kawakami T; Sato Y; Todo S; Itoh K
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients.
British journal of cancer 2004;90(8):1563-71.
2004: Sato Y; Maeda Y; Shomura H; Sasatomi T; Takahashi M; Une Y; Kondo M; Shinohara T; Hida N; Katagiri K; Sato K; Sato M; Yamada A; Yamana H; Harada M; Itoh K; Todo S
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.
British journal of cancer 2004;90(7):1334-42.
2004: Koga M; Komatsu N; Kawamoto N; Shichijo S; Itoh K; Yamada A
Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: heterotopic expression of SART3 on the surface of B-lineage leukemic cells.
Oncology reports 2004;11(4):785-9.
2004: Ishihara Yuki; Harada Mamoru; Azuma Koichi; Tamura Mayumi; Shomura Hiroki; Fujii Teruhiko; Itoh Kyogo; Shichijo Shigeki
HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.
International journal of oncology 2004;24(4):967-75.
2004: Takedatsu Hiroko; Shichijo Shigeki; Katagiri Kazuko; Sawamizu Hiromi; Sata Michio; Itoh Kyogo
Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):1112-20.
2004: Mine Takashi; Sato Yuji; Noguchi Masanori; Sasatomi Teruo; Gouhara Rumi; Tsuda Naotake; Tanaka Shoko; Shomura Hiroki; Katagiri Kazuko; Rikimaru Touru; Shichijo Shigeki; Kamura Toshiharu; Hashimoto Takashi; Shirouzu Kazuo; Yamada Akira; Todo Satoru; Itoh Kyogo; Yamana Hideaki
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):929-37.
2004: Harada Mamoru; Gohara Rumi; Matsueda Satoko; Muto Akira; Oda Tatsuya; Iwamoto Yoshiko; Itoh Kyogo
In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2659-67.
2004: Takedatsu Hiroko; Shichijo Shigeki; Azuma Kouichi; Takedatsu Hidetoshi; Sata Michio; Itoh Kyogo
Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients.
International journal of oncology 2004;24(2):337-47.
2004: Noguchi Masanori; Noda Shinshi; Yoshida Masaki; Ueda Shoichi; Shiraishi Taizo; Itoh Kyogo;
Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
International journal of urology : official journal of the Japanese Urological Association 2004;11(2):103-9.
2004: Kumamaru Wataru; Nakamura Seiji; Kadena Tsutomu; Yamada Akira; Kawamura Eiji; Sasaki Masanori; Ohyama Yukiko; Toyoshima Takeshi; Hayashida Jun-Nosuke; Itoh Kyogo; Shirasuna Kanemitsu
T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
International journal of cancer. Journal international du cancer 2004;108(5):686-95.
2004: Noguchi Masanori; Itoh Kyogo; Suekane Shigetaka; Yao Akihisa; Suetsugu Norie; Katagiri Kazuko; Yamada Akira; Yamana Hideaki; Noda Shinshi
Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Cancer science 2004;95(1):77-84.
2004: Tsuda Naotake; Mochizuki Kazuo; Harada Mamoru; Sukehiro Aki; Kawano Koichiro; Yamada Akira; Ushijima Kimio; Sugiyama Toru; Nishida Takashi; Yamana Hideaki; Itoh Kyogo; Kamura Toshiharu
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(1):60-72.
2004: Fukuda Kunie; Takao Yukari; Miyazaki Yuki; Itoh Kyogo; Yamada Akira
New type of natural antibodies reactive to cytotoxic T lymphocyte-directed cancer vaccine peptides.
Immunobiology 2004;209(3):245-53.
2004: Takao Yukari; Yamada Akira; Yutani Shigeru; Sata Michio; Itoh Kyogo
Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction.
Microbiology and immunology 2004;48(7):507-17.
2003: Shichijo Shigeki; Azuma Kohichi; Komatsu Nobukazu; Kawamoto Naoki; Takedatsu Hiroko; Shomura Hiroki; Sawamizu Hiromi; Maeda Yoshiaki; Ito Masaaki; Itoh Kyogo
Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes.
International journal of molecular medicine 2003;12(6):895-902.
2003: Ohkouchi Shinya; Kawamoto Naoki; Koga Makoto; Sakanashi Fumi; Shichijo Shigeki; Saijo Yasuo; Nukiwa Toshihiro; Itoh Kyogo; Yamada Akira
Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients.
European journal of immunology 2003;33(11):2964-73.
2003: Harada Mamoru; Kobayashi Kazuhiko; Matsueda Satoko; Nakagawa Masami; Noguchi Masanori; Itoh Kyogo
Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
The Prostate 2003;57(2):152-9.
2003: Sato Yuji; Shomura Hiroki; Maeda Yoshiaki; Mine Takashi; Une Yoshie; Akasaka Yoshinobu; Kondo Masao; Takahashi Shusaku; Shinohara Toshiki; Katagiri Kazuko; Sato Mika; Okada Shiori; Matsui Kanae; Yamada Akira; Yamana Hideaki; Itoh Kyogo; Todo Satoru
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.
Cancer science 2003;94(9):802-8.
2003: Azuma K; Shichijo S; Takedatsu H; Komatsu N; Sawamizu H; Itoh K
Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients.
British journal of cancer 2003;89(6):1079-85.
2003: Noguchi Masanori; Kobayashi Kazuhiko; Suetsugu Norie; Tomiyasu Katsurou; Suekane Shigetaka; Yamada Akira; Itoh Kyogo; Noda Shinshi
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
The Prostate 2003;57(1):80-92.
2003: Harada Mamoru; Noguchi Masanori; Itoh Kyogo
Target molecules in specific immunotherapy against prostate cancer.
International journal of clinical oncology / Japan Society of Clinical Oncology 2003;8(4):193-9.
2003: Tanaka Shoko; Harada Mamoru; Mine Takashi; Noguchi Masanori; Gohara Rumi; Azuma Koichi; Tamura Mayumi; Yamada Akira; Morinaga Akiko; Nishikori Misa; Katagiri Kazuko; Itoh Kyogo; Yamana Hideaki; Hashimoto Takashi
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):357-66.
2003: Kobayashi Kazuhiko; Noguchi Masanori; Itoh Kyogo; Harada Mamoru
Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Cancer science 2003;94(7):622-7.
2003: Mine Takashi; Gouhara Rumi; Hida Naoya; Imai Nobue; Azuma Kouichi; Rikimaru Touru; Katagiri Kazuko; Nishikori Misa; Sukehiro Aki; Nakagawa Masami; Yamada Akira; Aizawa Hisamichi; Shirouzu Kazuo; Itoh Kyogo; Yamana Hideaki
Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Cancer science 2003;94(6):548-56.
2003: Yamada Akira; Kawano Kouichiro; Koga Makoto; Takamori Shinzo; Nakagawa Masami; Itoh Kyogo
Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.
Cancer research 2003;63(11):2829-35.
2003: Kawamoto N; Yamada A; Ohkouchi S; Maeda T; Tanaka S; Hashimoto T; Saijo Y; Saijo S; Nukiwa T; Shichijo S; Aizawa H; Itoh K
IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients.
Tissue antigens 2003;61(5):352-61.
2003: Koga M; Shichijo S; Yamada A; Ashihara J; Sawamizu H; Kusukawa J; Itoh K
Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL.
Tissue antigens 2003;61(2):136-45.
2003: Azuma Koichi; Shichijo Shigeki; Maeda Yoshiaki; Nakatsura Tetsuya; Nonaka Yoichi; Fujii Teruhiko; Koike Kenta; Itoh Kyogo
Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Cancer research 2003;63(4):854-8.
2002: Nonaka Y; Tsuda N; Shichijo S; Ito M; Maeda Y; Harada M; Kamura T; Shigemori M; Itoh K
Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors.
Tissue antigens 2002;60(4):319-27.
2002: Tsuda N; Nonaka Y; Shichijo S; Yamada A; Ito M; Maeda Y; Harada M; Kamura T; Itoh K
UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour.
British journal of cancer 2002;87(9):1006-12.
2002: Maeda Y; Hida N; Niiya F; Katagiri K; Harada M; Yamana H; Kamura T; Takahashi M; Sato Y; Todo S; Itoh K
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients.
British journal of cancer 2002;87(7):796-804.
2002: Gohara Rumi; Imai Nobue; Rikimaru Toru; Yamada Akira; Hida Naoya; Ichiki Masao; Kawamoto Mayumi; Matsunaga Kazuko; Ashihara Junko; Yano Sayoko; Tamura Mayumi; Ohkouchi Shinya; Yamana Hideaki; Oizumi Kotaro; Itoh Kyogo
Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(5):439-44.
2002: Hida Naoya; Maeda Yoshiaki; Katagiri Kazuko; Takasu Hideo; Harada Mamoru; Itoh Kyogo
A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation.
Cancer immunology, immunotherapy : CII 2002;51(4):219-28.
2002: Komatsu Nobukazu; Shichijo Shigeki; Maeda Yoshiaki; Itoh Kyogo
Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system.
Journal of immunological methods 2002;263(1-2):169-76.
2002: Maeda Yoshiaki; Ito Masaaki; Harashima Nanae; Nakatsura Tetsuya; Hida Naoya; Imai Nobue; Sato Yuuji; Shichijo Shigeki; Todo Satoru; Itoh Kyogo
Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients.
International journal of cancer. Journal international du cancer 2002;99(3):409-17.
2002: Ohkouchi S; Yamada A; Imai N; Mine T; Harada K; Shichijo S; Maeda Y; Saijo Y; Nukiwa T; Itoh K
Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals.
Tissue antigens 2002;59(4):259-72.
2002: Yutani Shigeru; Tanaka Masatoshi; Mutsumoto Hajime; Imai Nobue; Sata Michio; Shichijo Shigeki; Harada Mamoru; Itoh Kyogo
Elevation of serum MAGE-4 protein levels and prediction of hepatocellular carcinogenesis in patients with liver cirrhosis.
Japanese journal of cancer research : Gann 2002;93(4):453-8.
2002: Sasatomi Teruo; Suefuji Yuichi; Matsunaga Kazuko; Yamana Hideaki; Miyagi Yoshiaki; Araki Yasumi; Ogata Yutaka; Itoh Kyogo; Shirouzu Kazuo
Expression of tumor rejection antigens in colorectal carcinomas.
Cancer 2002;94(6):1636-41.
2002: Nakatsura Tetsuya; Senju Satoru; Ito Masaaki; Nishimura Yasuharu; Itoh Kyogo
Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
European journal of immunology 2002;32(3):826-36.
2002: Suzuki Nobuaki; Maeda Yoshiaki; Tanaka Shoko; Hida Naoya; Mine Takashi; Yamamoto Koutaro; Oka Masaaki; Itoh Kyogo
Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer.
International journal of cancer. Journal international du cancer 2002;98(1):45-50.
2002: Tanaka Koji; Harashima Nanae; Niiya Fumihiko; Miyagi Yoshiaki; Hida Naoya; Ochi Mika; Imai Nobue; Harada Mamoru; Itoh Kyogo; Shichijo Shigeki
Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients.
Japanese journal of cancer research : Gann 2002;93(2):198-208.
2001: Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3950-62.
2001: Imai N; Harashima N; Ito M; Miyagi Y; Harada M; Yamada A; Itoh K
Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases.
International journal of cancer. Journal international du cancer 2001;94(2):237-42.
2001: Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Cancer research 2001;61(17):6459-66.
2001: Harada K; Yamada A; Yang D; Itoh K; Shichijo S
Binding of a SART3 tumor-rejection antigen to a pre-mRNA splicing factor RNPS1: a possible regulation of splicing by a complex formation.
International journal of cancer. Journal international du cancer 2001;93(5):623-8.
2001: Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Japanese journal of cancer research : Gann 2001;92(7):762-7.
2001: Koga C; Itoh K; Aoki M; Suefuji Y; Yoshida M; Asosina S; Esaki K; Kameyama T
Anxiety and pain suppress the natural killer cell activity in oral surgery outpatients.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2001;91(6):654-8.
2001: Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2001;19(3):346-51.
2001: Niiya F; Mine T; Toh U; Yamana H; Itoh K
[Cancer vaccine with peptides derived from tumor rejection antigens]
Nippon rinsho. Japanese journal of clinical medicine 2001;59 Suppl 4():438-42.
2001: Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
British journal of cancer 2001;84(7):915-9.
2001: Ito M; Shichijo S; Tsuda N; Ochi M; Harashima N; Saito N; Itoh K
Molecular basis of T cell-mediated recognition of pancreatic cancer cells.
Cancer research 2001;61(5):2038-46.
2001: Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K
Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.
Oncology reports 2001;8(2):369-72.
2001: Harashima N; Tanaka K; Sasatomi T; Shimizu K; Miyagi Y; Yamada A; Tamura M; Yamana H; Itoh K; Shichijo S
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
European journal of immunology 2001;31(2):323-32.
2001: Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
Viral immunology 2001;14(4):369-77.
2000: Sasatomi T; Yamana H; Shichijo S; Tanaka S; Okamura T; Ogata Y; Itoh K; Shirouzu K
Expression of the SART1 tumor-rejection antigens in colorectal cancers.
Diseases of the colon and rectum 2000;43(12):1754-8.
2000: Toh U; Yamana H; Sueyoshi S; Tanaka T; Niiya F; Katagiri K; Fujita H; Shirozou K; Itoh K
Locoregional cellular immunotherapy for patients with advanced esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4663-73.
2000: Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
The Journal of urology 2000;164(6):2090-5.
2000: Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
Expression of tumor-rejection antigens in gynecologic cancers.
Japanese journal of cancer research : Gann 2000;91(11):1177-84.
2000: Ito M; Shichijo S; Miyagi Y; Kobayashi T; Tsuda N; Yamada A; Saito N; Itoh K
Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes.
International journal of cancer. Journal international du cancer 2000;88(4):633-9.
2000: Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
The British journal of ophthalmology 2000;84(10):1130-4.
2000: Yamana H; Itoh K
[Specific immunotherapy with cancer vaccines]
Gan to kagaku ryoho. Cancer & chemotherapy 2000;27(10):1477-88.
2000: Murayama K; Kobayashi T; Imaizumi T; Matsunaga K; Kuramoto T; Shigemori M; Shichijo S; Itoh K
Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(5):511-8.
2000: Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
Cancer research 2000;60(17):4830-7.
2000: Kawano K; Gomi S; Tanaka K; Tsuda N; Kamura T; Itoh K; Yamada A
Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.
Cancer research 2000;60(13):3550-8.
2000: Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
International journal of oncology 2000;17(1):29-32.
2000: Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Urological research 2000;28(3):178-84.
2000: Kamizono S; Hiromatsu Y; Seki N; Bednarczuk T; Matsumoto H; Kimura A; Itoh K
A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese.
Clinical endocrinology 2000;52(6):759-64.
2000: Kamizono S; Yamada K; Seki N; Higuchi T; Kimura A; Nonaka K; Itoh K
Susceptible locus for obese type 2 diabetes mellitus in the 5'-flanking region of the tumor necrosis factor-alpha gene.
Tissue antigens 2000;55(5):449-52.
2000: Mine T; Harada K; Matsumoto T; Yamana H; Shirouzu K; Itoh K; Yamada A
CDw108 expression during T-cell development.
Tissue antigens 2000;55(5):429-36.
2000: Inoue Y; Nakao M; Matsunaga K; Kikuchi M; Gomi S; Toh U; Takamori S; Yamana H; Itoh K
Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(3):296-303.
2000: Niiya F; Nishizaka S; Matsunaga K; Koufuji K; Mori M; Katai H; Yamana H; Itoh K
Expression of SART3 tumor-rejection antigen in gastric cancers.
Japanese journal of cancer research : Gann 2000;91(3):337-42.
2000: Seki N; Yamada A; Suefuji Y; Mine T; Tanaka S; Gomi S Y; Kawagoe N; Koufuji K; Itoh K
Establishment and epitope analysis of allo-specific cytotoxic T lymphocytes at a tumor site recognizing a spouse's HLA-A0206 molecule.
American journal of reproductive immunology (New York, N.Y. : 1989) 2000;43(3):167-73.
2000: Nakao M; Shichijo S; Imaizumi T; Inoue Y; Matsunaga K; Yamada A; Kikuchi M; Tsuda N; Ohta K; Takamori S; Yamana H; Fujita H; Itoh K
Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(5):2565-74.
2000: Harada K; Yamada A; Mine T; Kawagoe N; Takasu H; Itoh K
Mouse homologue of the human SART3 gene encoding tumor-rejection antigen.
Japanese journal of cancer research : Gann 2000;91(2):239-47.
1999: Date Y; Seki N; Kamizono S; Higuchi T; Hirata T; Miyata K; Ohkuni M; Tatsuzawa O; Yokota S; Joo K; Ueda K; Sasazuki T; Kimura A; Itoh K; Kato H
Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes.
Arthritis and rheumatism 1999;42(12):2577-82.
1999: Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
Expression of the tumor-rejection antigen SART1 in brain tumors.
International journal of cancer. Journal international du cancer 1999;83(6):760-4.
1999: Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(9):4994-5004.
1999: Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Japanese journal of cancer research : Gann 1999;90(9):1007-15.
1999: Seki N; Yamaguchi K; Yamada A; Kamizono S; Sugita S; Taguchi C; Matsuoka M; Matsumoto H; Nishizaka S; Itoh K; Mochizuki M
Polymorphism of the 5'-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis.
The Journal of infectious diseases 1999;180(3):880-3.
1999: Seki N; Kamizono S; Yamada A; Higuchi T; Matsumoto H; Niiya F; Kimura A; Tsuchiya K; Suzuki R; Date Y; Tomita T; Itoh K; Ochi T
Polymorphisms in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis.
Tissue antigens 1999;54(2):194-7.
1999: Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Cancer research 1999;59(16):4056-63.
1999: Kamizono S; Yamada A; Higuchi T; Kato H; Itoh K
Analysis of tumor necrosis factor-alpha production and polymorphisms of the tumor necrosis factor-alpha gene in individuals with a history of Kawasaki disease.
Pediatrics international : official journal of the Japan Pediatric Society 1999;41(4):341-5.
1999: Yamada A; Kawano K; Harashima N; Niiya F; Nagai K; Kobayashi T; Mine T; Ushijima K; Nishida T; Itoh K
Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.
Cancer immunology, immunotherapy : CII 1999;48(2-3):147-52.
1999: Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 1999;81(3):459-66.
1999: Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 1999;81(3):387-94.
1999: Yamada A; Kubo K; Takeshita T; Harashima N; Kawano K; Mine T; Sagawa K; Sugamura K; Itoh K
Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(7):4094-100.
1999: Kawamoto M; Shichijo S; Imai Y; Imaizumi T; Koga T; Yanaga H; Itoh K
Expression of the SART-1 tumor rejection antigen in breast cancer.
International journal of cancer. Journal international du cancer 1999;80(1):64-7.
1998: Matsumoto H; Shichijo S; Kawano K; Nishida T; Sakamoto M; Itoh K
Expression of the SART-1 antigens in uterine cancers.
Japanese journal of cancer research : Gann 1998;89(12):1292-5.
1998: Gotoh M; Shichijo S; Hoshino T; Imai Y; Imaizumi T; Inoue Y; Takasu H; Yamaoka T; Itoh K
Sequence analysis of genes encoding rodent homologues of the human tumor-rejection antigen SART-1.
Japanese journal of cancer research : Gann 1998;89(8):849-54.
1998: Sakaguchi M; Sugita S; Sagawa K; Itoh K; Mochizuki M
Cytokine production by T cells infiltrating in the eye of uveitis patients.
Japanese journal of ophthalmology 1998;42(4):262-8.
1998: Higuchi T; Seki N; Kamizono S; Yamada A; Kimura A; Kato H; Itoh K
Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese.
Tissue antigens 1998;51(6):605-12.
1998: Shichijo S; Nakao M; Imai Y; Takasu H; Kawamoto M; Niiya F; Yang D; Toh Y; Yamana H; Itoh K
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.
The Journal of experimental medicine 1998;187(3):277-88.
1997: Suekane S; Nakao M; Inoue M; Noda S; Itoh K
Histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of patient with testicular embryonal cancer.
Japanese journal of cancer research : Gann 1997;88(12):1181-9.
1997: Tsuzurahara S; Sata M; Iwamoto O; Shichijo S; Kojiro M; Tanikawa K; Itoh K
Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis.
Japanese journal of cancer research : Gann 1997;88(9):915-8.
1997: Noguchi M; Miyajima J; Itoh K; Noda S
Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction.
International journal of urology : official journal of the Japanese Urological Association 1997;4(4):374-9.
1997: Nagai K; Yamada A; Eguchi H; Kato H; Itoh K
HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilms' tumor.
Pediatric research 1997;42(1):122-7.
1997: Hoshino T; Suzuki R; Tsuruta Y; Matsutani T; Kikuchi M; Kawamoto M; Gouhara R; Shiraishi T; Mochizuki M; Itoh K; Oizumi K
Non-restricted T cell receptor (TCR)-V alpha and -V beta gene usage in patients with pulmonary sarcoidosis.
Clinical and experimental immunology 1997;108(3):529-38.
1997: Yamada A; Hara A; Inoue M; Kamizono S; Higuchi T; Itoh K
Beta 2-integrin-mediated signal up-regulates counterreceptor ICAM-1 expression on human monocytic cell line THP-1 through tyrosine phosphorylation.
Cellular immunology 1997;178(1):9-16.
1997: Nakao M; Sata M; Saitsu H; Yutani S; Kawamoto M; Kojiro M; Itoh K
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cellular immunology 1997;177(2):176-81.
1997: Toh U; Yamana H; Nakao M; Imai Y; Seki N; Takasu H; Kaneshige T; Fujita H; Shirouzu K; Itoh K
HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers.
Cellular immunology 1997;177(2):137-43.
1997: Shichijo S; Hoshino T; Koufuji K; Hayashi A; Kawamoto M; Kikuchi M; Higuchi T; Ichiki M; Oizumi K; Itoh K
Detection of MAGE-4 protein in sera of lung cancer patients.
Japanese journal of cancer research : Gann 1997;88(4):414-9.
1997: Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
International journal of cancer. Journal international du cancer 1997;70(6):631-8.
1997: Gohara R; Nakao M; Ogata Y; Isomoto H; Oizumi K; Itoh K
Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
Japanese journal of cancer research : Gann 1997;88(2):198-204.
1997: Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cellular immunology 1997;175(2):101-10.
1997: Sudo T; Kuramoto T; Komiya S; Inoue A; Itoh K
Expression of MAGE genes in osteosarcoma.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 1997;15(1):128-32.
1997: Iwamoto O; Nagao Y; Shichijo S; Eura M; Kameyama T; Itoh K
Detection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma.
International journal of cancer. Journal international du cancer 1997;70(3):287-90.
1996: Miyajima J; Imai Y; Nakao M; Noda S; Itoh K
Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(6):399-404.
1996: Shichijo S; Yamada A; Sagawa K; Iwamoto O; Sakata M; Nagai K; Itoh K
Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine.
Japanese journal of cancer research : Gann 1996;87(7):751-6.
1996: Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
International immunology 1996;8(5):799-803.
1996: Toh U; Yamana H; Fujita H; Toh Y; Fujii T; Kubo K; Yamada A; Shichijo S; Itoh K
A monoclonal antibody KIS-1 recognizing a new membrane antigen on human squamous-cell carcinoma.
International journal of cancer. Journal international du cancer 1996;66(5):600-6.
1996: Tamai M; Sagawa K; Kawabata R; Inoue A; Itoh K
Production of IL-6 by T cells from the femoral head of patients with rapidly destructive coxopathy (RDC).
Clinical and experimental immunology 1996;103(3):506-13.
1996: Hoshino T; Ohta A; Nakao M; Ota T; Inokuchi T; Matsueda S; Gouhara R; Yamada A; Itoh K; Oizumi K
TCR gamma delta + T cells in peripheral blood of patients with adult Still's disease.
The Journal of rheumatology 1996;23(1):124-9.
1996: Sagawa K; Mochizuki M; Katagirl K; Tsuboi I; Sugita S; Mukaida N; Itoh K
In vitro effects of immunosuppressive agents on cytokine production by HTLV-I-infected T cell clones derived from the ocular fluid of patients with HTLV-I uveitis.
Microbiology and immunology 1996;40(5):373-9.
1995: Yamada A; Kataoka A; Shichijo S; Kamura T; Imai Y; Nishida T; Itoh K
Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors.
International journal of cancer. Journal international du cancer 1995;64(6):388-93.
1995: Hoshino T; Itoh K; Gouhara R; Yamada A; Tanaka Y; Ichikawa Y; Azuma M; Mochizuki M; Oizumi K
Spontaneous production of various cytokines except IL-4 from CD4+ T cells in the affected organs of sarcoidosis patients.
Clinical and experimental immunology 1995;102(2):399-405.
1995: Nakao M; Yamana H; Imai Y; Toh Y; Toh U; Kimura A; Yanoma S; Kakegawa T; Itoh K
HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma.
Cancer research 1995;55(19):4248-52.
1995: Shichijo S; Tsunosue R; Kubo K; Kuramoto T; Tanaka Y; Hayashi A; Itoh K
Establishment of an enzyme-linked immunosorbent assay (ELISA) for measuring cellular MAGE-4 protein on human cancers.
Journal of immunological methods 1995;186(1):137-49.
1995: Shichijo S; Tsunosue R; Masuoka K; Natori H; Tamai M; Miyajima J; Sagawa K; Itoh K
Expression of the MAGE gene family in human lymphocytic leukemia.
Cancer immunology, immunotherapy : CII 1995;41(2):90-103.
1995: Takahashi K; Shichijo S; Noguchi M; Hirohata M; Itoh K
Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.
Cancer research 1995;55(16):3478-82.
1995: Toh Y; Yamana H; Shichijo S; Fujita H; Tou U; Sakaguchi M; Kakegawa T; Itoh K
Expression of MAGE-1 gene by esophageal carcinomas.
Japanese journal of cancer research : Gann 1995;86(8):714-7.
1995: Shichijo S; Hayashi A; Takamori S; Tsunosue R; Hoshino T; Sakata M; Kuramoto T; Oizumi K; Itoh K
Detection of MAGE-4 protein in lung cancers.
International journal of cancer. Journal international du cancer 1995;64(3):158-65.
1995: Tsuboi I; Tanaka H; Nakao M; Shichijo S; Itoh K
Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production.
Cytokine 1995;7(4):372-9.
1995: Sagawa K; Mochizuki M; Masuoka K; Katagiri K; Katayama T; Maeda T; Tanimoto A; Sugita S; Watanabe T; Itoh K
Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production.
The Journal of clinical investigation 1995;95(2):852-8.
1995: Sakaguchi M; Kato H; Nishiyori A; Sagawa K; Itoh K
Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2- or V beta 8- CD4+ T helper cells.
Clinical and experimental immunology 1995;99(2):276-82.
1995: Masuoka K; Sagawa K; Mochizuki M; Oizumi K; Itoh K
Polyclonal use of T-cell receptor alpha for human T-cell lymphotropic virus type 1-infected T cells.
Investigative ophthalmology & visual science 1995;36(1):254-8.
1994: Hoshino T; Yamada K; Masuoka K; Tsuboi I; Itoh K; Nonaka K; Oizumi K
Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus.
Diabetes research and clinical practice 1994;25(2):97-102.
1994: Seito D; Morita T; Masuoka K; Maeda T; Saya H; Itoh K
Polyclonal uses of T-cell receptor (TCR)alpha and beta genes for cytotoxic T lymphocytes in human metastatic melanoma: possible involvement of TCR alpha in tumor-cell recognition.
International journal of cancer. Journal international du cancer 1994;58(4):497-502.
1994: Kharkevitch D D; Seito D; Balch G C; Maeda T; Balch C M; Itoh K
Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma.
International journal of cancer. Journal international du cancer 1994;58(3):317-23.
1994: Itoh K; Umezu Y; Morita T; Saya H; Seito D; Augustus L B; Nakao M; Sakata M; Miyajima J; Masuoka K
Increase in the capability of interleukin 2 gene-transduced renal cell carcinoma cells to induce cytotoxic lymphocytes.
The Kurume medical journal 1994;41(2):53-63.
1994: Nishiyori A; Fukuda K; Itoh K; Kato H
Genotype-phenotype agreement of aldehyde dehydrogenase 2 in 120 healthy Japanese.
The Kurume medical journal 1994;41(3):117-21.
1993: Hirohashi N; Nakao M; Kubo K; Yamada A; Shichijo S; Hara A; Sagawa K; Itoh K
A novel antigen (H47 Ag) on human lymphocytes involved in T cell activation.
Cellular immunology 1993;152(2):371-82.
1993: Umezu Y; Augustus L B; Seito D; Hayakawa K; Ross M I; Eton O; Swanson D A; Itoh K
Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation.
Cancer immunology, immunotherapy : CII 1993;37(6):392-9.
1993: Nakao M; Kubo K; Hara A; Hirohashi N; Futagami E; Shichijo S; Sagawa K; Itoh K
A monoclonal antibody (H227) recognizing a new epitope of 4F2 molecular complex associated with T cell activation.
Cellular immunology 1993;152(1):226-33.
1993: Hoshino T; Yamada A; Honda J; Imai Y; Nakao M; Inoue M; Sagawa K; Yokoyama M M; Oizumi K; Itoh K
Tissue-specific distribution and age-dependent increase of human CD11b+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(4):2237-46.
1993: Fujimaki W; Itoh K; An T; Gano J B; Ross M I; Mansfield P F; Balch C M; Augustus L B; Karkevitch D D; Johnston D
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
Cancer biotherapy 1993;8(4):307-18.
1992: Salmeron M A; Balch C M; Ross M I; Itoh K
Role of uncultured human melanoma cells in the proliferation of autologous tumor-specific cytotoxic T lymphocytes.
Cellular immunology 1992;143(1):228-37.
1992: Itoh K; Salmeron M A; Morita T; Seito D; Mansfield P F; Ross M I; Balch C M; Augustus L B
Distribution of autologous tumor-specific cytotoxic T lymphocytes in human metastatic melanoma.
International journal of cancer. Journal international du cancer 1992;52(1):52-9.
1992: Morita T; Salmeron M A; Hayakawa K; Swanson D A; von Eschenbach A C; Itoh K
T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Regional immunology 1992;4(4):225-35.
1992: Nanno M; Seki H; Ioannides C G; Itoh K; Morkowski J J; Day N K; Good R A; Platsoucas C D
Disulfide-linked and non-disulfide-linked gamma/delta T-cell antigen receptors: differential expression on T-cell lines and clones derived from normal donors and patients with primary immunodeficiency disorders.
Anticancer research 1992;12(4):1069-78.
1992: Hayakawa K; Morita T; Augustus L B; von Eschenbach A C; Itoh K
Human renal-cell carcinoma cells are able to activate natural killer cells.
International journal of cancer. Journal international du cancer 1992;51(2):290-5.
1992: Nanno M; Seki H; Mathioudakis G; Suzuki R; Itoh K; Ioannides C G; Suzuki S; Chen P F; Platsoucas C D
Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors.
European journal of immunology 1992;22(3):679-87.
1992: Morita T; Salmeron M A; Moser R P; Ross M I; Itoh K
Oligoclonal expansion of V beta 8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma.
Clinical & experimental metastasis 1992;10(1):69-76.
1992: Salmeron M A; Morita T; Seki H; Platsoucas C D; Itoh K
Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
Cancer immunology, immunotherapy : CII 1992;35(3):211-7.
1991: Morkowski J J; Nanno M; Chen P F; Itoh K; Ioannides C G; Kruzel E; Becker F F; Platsoucas C D
IL-2-dependent murine T-cell lines and clones expressing gamma/delta T-cell antigen receptors. I. Functional and biochemical characterization.
Scandinavian journal of immunology 1991;34(6):779-94.
1991: Itoh K; Balch C M; Murray J L; Parkinson D R; Markowitz A B; Talpaz M; Lee K; Zukiwski A A; Ross M I; Legha S S
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
In vivo (Athens, Greece) 1991;5(6):647-53.
1991: Hayakawa K; Salmeron M A; Parkinson D R; Markowitz A B; von Eschenbach A C; Legha S S; Balch C M; Ross M I; Augustus L B; Itoh K
Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):313-25.
1991: Mansfield P F; Salmeron M A; Rosenblum M G; Itoh K
Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
International journal of cancer. Journal international du cancer 1991;49(3):356-61.
1991: Ioannides C G; Rashed S; Fisk B; Fan D; Itoh K; Freedman R S
Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
Lymphokine and cytokine research 1991;10(4):307-15.
1991: Hayakawa K; Salmeron M A; Kornbluth J; Bucana C; Itoh K
The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(7):2453-60.
1991: Zhang R D; Price J E; Schackert G; Itoh K; Fidler I J
Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis.
Cancer research 1991;51(8):2029-35.
1991: Itoh K; Hayakawa K; Salmeron M A; Legha S S; Murray J L; Talpaz M; Balch C M; Parkinson D R; Lee K; Zukiwski A A
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
Cancer immunology, immunotherapy : CII 1991;33(4):238-46.
1991: Mansfield P F; Rosenblum M G; Murray J L; Itoh K
Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Cancer immunology, immunotherapy : CII 1991;33(4):247-54.
1990: Riley L B; Pellis N R; Schantz S P; Freedman R S; Balch C M; Itoh K
Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients.
International journal of cancer. Journal international du cancer 1990;46(5):785-91.
1990: Kim T Y; von Eschenbach A C; Filaccio M D; Hayakawa K; Parkinson D R; Balch C M; Itoh K
Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
Cancer research 1990;50(17):5263-8.
1990: Balch C M; Riley L B; Bae Y J; Salmeron M A; Platsoucas C D; von Eschenbach A; Itoh K
Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.
Archives of surgery (Chicago, Ill. : 1960) 1990;125(2):200-5.
1990: Schackert G; Price J E; Zhang R D; Bucana C D; Itoh K; Fidler I J
Regional growth of different human melanomas as metastases in the brain of nude mice.
The American journal of pathology 1990;136(1):95-102.
1989: Parkinson D R; Talpaz M; Lee K H; Legha S; Markowitz A B; Itoh K; Balch C M; Murray J L; Zukiwski A A; Benjamin R S
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.
Cancer treatment reviews 1989;16 Suppl A():39-48.
1989: Seki H; Nanno M; Chen P F; Itoh K; Ioannides C; Good R A; Platsoucas C D
Molecular heterogeneity of gamma delta T-cell antigen receptors expressed by CD4- CD8- T-cell clones from normal donors: both disulfide- and non-disulfide-linked receptors are delta TCS1+.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(7):2326-30.
1989: Itoh K; Pellis N R; Balch C M
Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Cancer immunology, immunotherapy : CII 1989;29(1):57-62.
1988: Itoh K; Platsoucas C D; Balch C M
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
The Journal of experimental medicine 1988;168(4):1419-41.
1988: Itoh K; Balch C M; Platsoucas C D
Monocyte-independent interleukin-2 production and proliferation of human T cells in response to murine hybridomas expressing the OKT3 monoclonal antibody: interleukin-1 is not required for T-cell proliferation.
Cellular immunology 1988;115(1):36-56.
1988: Itoh K; Balch C M; Trial J; Platsoucas C D
CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production.
Cellular immunology 1988;114(2):257-71.

Sign-in to see more